| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7388952 | Value in Health | 2018 | 7 Pages |
Abstract
Pegvisomant is still a good option for acromegaly treatment, but pasireotide seems to be a promising alternative. Nevertheless, other important key factors such as drug costs and effectiveness (real-world results) should be taken into account when selecting acromegaly treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
LetÃcia P. MSc, Vinicius L. MSc, Fernanda S. MSc, Fernando PhD, Roberto PhD,